Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Insilico Medicine has raised $123.0M in total funding. The most recent round was Series E. The last funding was announced in March 2025.
Insilico Medicine's investors include Sequoia Capital, HSG, Eli Lilly, Qiming Venture Partners, B Capital.
Insilico Medicine is headquartered in Cambridge, United States.
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Insilico Medicine is at the Series E stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Insilico Medicine — Funding & Investors." VCBacked, March 13, 2025, https://www.vcbacked.co/company/insilico-medicine. Accessed July 20, 2026.
VCBacked. (2025). Insilico Medicine — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/insilico-medicine
{{cite web |title=Insilico Medicine — Funding & Investors |url=https://www.vcbacked.co/company/insilico-medicine |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated